Lupin Limited, a pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). It offers formulations for use in the therapeutic areas of cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastrointestinal, anti-infective, nonsteroidal anti-inflammatory drug therapy, respiratory, women's health, and anti-tuberculosis. The company is also involved in the provision of biosimilar and over-the-counter products; specialty products; and drug discovery and development programs in the therapeutic areas of oncology, immunology, and metabolic disorders, as well as bio clinical research activities. Lupin Limited network consists of 18 labs, 280 LupiMitra collection centers, and 450 pick-up points. It operates in India, the United States, the United Kingdom, South Africa, Australia, the Philippines, Germany, the Netherlands, Mexico, and Brazil. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001 as a result of its amalgamation with Lupin Laboratories Limited. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.
P/E ratio for Lupin Limited (LUPIN.NS)
P/E ratio as of 2023: 38.61
According to Lupin Limited's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 38.61. At the end of 2022 the company had a P/E ratio of 68.55.
P/E ratio history for Lupin Limited from 2003 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 38.61 |
| 2022 | 68.55 |
| 2021 | -22.20 |
| 2020 | 38.02 |
| 2019 | -99.09 |
| 2018 | 57.13 |
| 2017 | 139.75 |
| 2016 | 25.49 |
| 2015 | 29.32 |
| 2014 | 37.51 |
| 2013 | 22.76 |
| 2012 | 21.60 |
| 2011 | 27.33 |
| 2010 | 21.63 |
| 2009 | 21.38 |
| 2008 | 12.22 |
| 2007 | 10.94 |
| 2006 | 17.60 |
| 2005 | 26.25 |
| 2004 | 26.57 |
| 2003 | 20.89 |